Pharmacological overview and future perspectives of cholinergic therapy in Alzheimer's disease

Current Drug Therapy

Volumn 4, Issue 1, 2009, Pages 65-72

  Ogura, Hiroo ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ARECOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HUPERZINE A; PHENSERINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; GLAUCOMA; HIPPOCAMPUS; HUMAN; LIVER TOXICITY; MYASTHENIA GRAVIS; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SIDE EFFECT;

EID: 65349120051     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488509787081868     Document Type: Review

References (86)

1. Loewi O. Uber humorale Ubertragbarkeit der Herznervenwirkung. Pflugers Arch 1921; 189: 239-42.
2. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr 1907; 64: 146-8.
3. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitterrelated enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459-96.
4. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
5. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1: 189.
6. Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ. Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res 1978; 159: 477-81.
7. Gottfries CG, Adolfsson R, Aquilonius SM, et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol. Aging 1983; 4: 261-71.
8. Rossor M, Fahrenkrug J, Emson P, Mountjoy C, Iversen L, Roth M. Reduced cortical choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide. Brain Res 1980; 201: 249-53.
9. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457-59.
10. Bowen DM, Benton JS, Spillane JA, Smith CC, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982; 57: 191-202.
11. Woolf NJ, Eckenstein F, Butcher LL. Cholinergic systems in the rat brain: I. projections to the limbic telencephalon. Brain Res Bull 1984; 13: 751-84.
12. Woolf NJ, Butcher LL. Cholinergic systems in the rat brain: II. Projections to the interpeduncular nucleus. Brain Res Bull 1985; 14: 63-83.
13. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9.
14. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30: 113-21.
15. Izquierdo I. Mechanism of action of scopolamine as an amnestic. Trends Pharmacol Sci 1989; 10: 175-7.
16. Wilson WJ, Cook JA. Cholinergic manipulations and passive avoidance in the rat: effects on acquisition and recall. Acta Neurobiol Exp (Wars) 1994; 54: 377-91.
17. Ogura H, Aigner TG. MK-801 impairs recognition memory in rhesus monkeys: comparison with cholinergic drugs. J Pharmacol Exp Ther 1993; 266: 60-4.
18. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14.
19. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90.
20. Levy R. Choline in Alzheimers disease. Lancet 1978; 2: 944-45.
21. Renvoize EB, Jerram T. Choline in Alzheimer's disease. N Engl J Med 1979; 301: 330.
22. Christie JE, Shering A, Ferguson J, Glen AI. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981; 138: 46-50.
23. Tariot PN, Cohen RM, Welkowitz JA, et al. Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 1988; 45: 901-5.
24. Wettstein A, Spiegel R. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology (Berl) 1984; 84: 572-3.
25. Taylor P. Anticholinesterase agents. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics (Tenth ed), McGraw-Hill, New York 2001; 175-191.
26. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004; 50: 433-40.
27. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-7.
28. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 2000; 22: 609-13.
29. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS. Physostigmine: improvement of long-term memory processes in normal humans. Science 1978; 201: 272-74.
30. Muramoto O, Sugishita M, Sugita H, Toyokura Y. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Arch Neurol 1979; 36: 501-3.
31. Peters BH, Levin HS. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol 1979; 6: 219-21.
32. Ashford JW, Soldinger S, Schaeffer J, Cochran L, Jarvik LF. Physostigmine and its effect on six patients with dementia. Am J Psychiatry 1981; 138: 829-30.
33. Mohs RC, Davis KL. A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease. Neurobiol Aging 1982; 3: 105-10.
34. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139: 1421-24.
35. Levin HS, Peters BH. Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease. Ann Neurol 1984; 15: 210.
36. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142: 28-33.
37. Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Psychopharmacology (Berl) 1985; 87: 147-51.
38. Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 627-36.
39. Caltagirone C, Gainotti G, Masullo C. Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 1982; 16: 247-9.
40. Caltagirone C, Albanese A, Gainotti G, Masullo C. Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers Presenile Dementia. Int J Neurosci 1983; 18: 143-7.
41. Wettstein A. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Ann Neurol 1983; 13: 210-12.
42. Freeman SE, Dawson RM. Tacrine: a pharmacological review. Prog Neurobiol 1991; 36: 257-77.
43. Summers WK, Viesselman JO, Marsh GM, Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry 1981; 16: 145-53.
44. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-5.
45. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebocontrolled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327: 1253-9.
46. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992; 268: 2523-9.
47. Winblad B, Kilander L, Eriksson S, et al. Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65.
48. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459-69.
49. Korczn AD, Reichmann H. Dementia with Lewy bodies. J Neurol Sci 2006; 248: 3-8.
50. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984; 15: 415-8.
51. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 413-21.
52. Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 2007; 23(6): 401-5.
53. Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry 2007; 22: 890-5.
54. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20: 938-44.
55. McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000; 15: 387-92.
56. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis 2007; 11: 509-19.
57. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
58. Klein J. Phenserine. Expert Opin. Investig. Drugs 2007; 16: 1087-97.
59. Lahiri DK, Alley GM, Tweedie D, Chen D, Greig NH. Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease. Neuromol Med 2007; 9: 157-68.
60. Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Behav 2003; 75: 675-86.
61. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
62. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-11.
63. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7.
64. Fisher A, Pittel Z, Haring R, et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 2003; 20: 349-56.
65. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003; 54: 235-8.
66. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007; 68: 1726-9.
67. Takada Y, Yonezawa A, Kume T, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003; 306: 772-7.
68. Arias E, Gallego-Sandin S, Villarroya M, Garcia AG, Lopez MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 2005; 315: 1346-53.
69. Akasofu S, Kosasa T, Kimura M, Kubota A. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 2003; 472: 57-63.
70. Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport 1998; 9: 1519-22.
71. Kimura M, Akasofu S, Ogura H, Sawada K. Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. Brain Res 2005; 1047: 72-84.
72. Kimura M, Komatsu H, Ogura H, Sawada K. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neurosci Lett 2005; 391: 17-21.
73. Zhang HY, Tang XC. Huperzine B: a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells. Neurosci Lett 2000; 292: 41-4.
74. Zhou J, Fu Y, Tang XC. Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett 2001; 306: 53-6.
75. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006; 51: 474-86.
76. Akasofu S, Kimura M, Kosasa T, Ogura H, Sawada K. Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (NMDA) toxicity. Eur J Pharmacol 2006; 530: 215-22.
77. Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006; 149: 998-1012.
78. Meunier J, Ieni J, Maurice T. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther 2006; 317: 1307-19.
79. Fujiki M, Kobayashi H, Uchida S, Inoue R, Ishii K. Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats. Brain Res 2005; 1043: 236-41.
80. Lorrio S, Sobrado M, Arias E, Roda JM, Garcia AG, Lopez MG. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J Pharmacol Exp Ther 2007; 322: 591-9.
81. Kaneko N, Okano H, Sawamoto K. Role of the cholinergic system in regulating survival of newborn neurons in the adult mouse dentate gyrus and olfactory bulb. Genes Cells 2006; 11: 1145-59.
82. Kotani S, Yamauchi T, Teramoto T, Ogura H. Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience 2006; 142: 505-14.
83. Mohapel P, Leanza G, Kokaia M, Lindvall O. Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning. Neurobiol Aging 2005; 26: 939-46.
84. Cooper-Kuhn CM, Winkler J, Kuhn HG. Decreased neurogenesis after cholinergic forebrain lesion in the adult rat. J Neurosci Res 2004; 77: 155-65.
85. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 2000; 22: 89-95.
86. Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine 2007; 14: 289-300.